Tag:
Mergers and Acquisitions
Latest Headlines
Latest Headlines
With Seroquel petition denied, AZ needs M&A
The FDA has officially denied AstraZeneca's petition to hold off generic versions of its antipsychotic drug Seroquel .
Generics deals drive increase in pharma M&A
Pharma M&A activity is heating up, particularly among medium-sized companies, and shows signs of accelerating further, MarketWatch reports.
Viehbacher up on Boston, emerging markets, down on corporate innovation
Sanofi ( $SNY ) CEO Chris Viehbacher ( photo ) managed to parlay one personal appearance into a half-dozen different headlines. Development strategies? Check. M&A interest? Check. Job creation?...
Abcam's $155M Epitomics buyout expands antibody business
Bidding to up its game in the antibody business, the U.K.'s Abcam has snapped up California-based Epitomics for $155 million.
GSK to add hundreds to Chinese sales force, CEO says
GlaxoSmithKline ( $GSK ) is steaming ahead in China. CEO Andrew Witty ( photo ) tells Bloomberg he plans to add "a few hundred" sales folks to back up products his company is introducing there. That's on top of 700 hires in 2011. And, Witty said, he'd like to augment his Chinese operations with some M&A, too.
Chinese pharmas feel the squeeze of healthcare reform
Even though China is set to become the second-largest drug market by 2020, all is not rosy for its native drugmakers. A government push to drive down costs for healthcare end users is pressuring pharma companies that call that vast country home, with 5 of them issuing profit warnings in recent weeks.
Analysts eye Big Pharma suitors for Vivus
Will a Big Pharma company swoop in to acquire Vivus ( $VVUS ), now that its obesity drug Qnexa has an FDA advisory panel's recommendation? Analysts say Bristol-Myers Squibb ( $BMY ), Merck ( $MRK ),...
Vivus basks in limelight of rampant M&A speculation
In yet another sign of just how quickly biotech investors can change their minds, Bloomberg is running a piece today speculating on which Big Pharma company is most likely to swoop in and pay a big...
Bayer cuts debt for freedom to make 'significant' acquisition
Bayer will cut its debt this year to €6 billion, or $8 billion, to give it more financing options as it looks for M&A targets.
Field narrows in contest for Pfizer's nutrition unit
The contest for Pfizer's nutrition unit is heating up.
